Article
Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach.
Oncology research and treatment - 1 Jan 2022
Mauri Davide, Kamposioras Konstantinos, Matthaios Dimitrios, Tolia Maria, Nixon Ioanna, Dambrosio Mario, Zarkavelis Georgios, Papadimitriou Konstantinos, Petricevic Branka, Kountourakis Pantelis, Kopecky Jindrich, Grašič Kuhar Cvetka, Popovic Lazar, Chilingirova Nataliya P, De Mello Ramon Andrade, Dedić Plavetić Natalija, Katsanos Konstantinos, Mostert Bianca, Alongi Filippo, de Bari Berardino, Corradini Stefanie, Kampletsas Eleytherios, Gazouli Ioanna, Gkoura Stefania, Amylidi Anna-Lea, Valachis Antonios
Abstract excerpt
BACKGROUND: Management of Ras wild-type colorectal cancer (CRC) patients upon disease progression after the successful use of targeted treatment with anti-EGFR monoclonal antibodies and backbone chemotherapy remains a clinical challenge. SUMMARY: Development of treatment resistance with prevalence of preexisting RAS mutated clones, RAS mutation conversion, truncation of extracellular receptor domains as well as...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.